Wegovy generally follows a higher dosing schedule than Ozempic, reaching up to 2.4 mg per week
GLP-1 slows down gastric emptying and suppresses appetite by promoting satiety and inhibiting hunger through the central nervous system, thereby leading to BW loss [38, 39]
This is the single most important point for dose-selection decisions going forward and is the reason the 9 mg arm and the new 4 mg maintenance dose are under such close scrutiny
These findings suggested that the therapeutic effects of GLP-1 are limited in NAFLD patients with lower GLP-1R expressions
GLP-1 provides the appetite suppression foundation, but GIP fundamentally changes how the body responds metabolically in ways that dramatically amplify weight loss beyond what GLP-1 alone achieves
There is variability across drugs [169,170,171,172]